Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Loargys Coverage Criteria Update | Open…
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Loargys (pegzilarginase-nbln) Coverage Criteria for Arginase 1 Deficiency

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    CareSource Arkansas PASSE medical prior authorization coverage for Loargys in adult and pediatric members at least 2 years of age with confirmed arginase 1 deficiency, specialist involvement, qualifying biochemical or genetic confirmation, elevated plasma arginine despite dietary protein restriction, and continued dietary protein restriction.

    Policy Summary
    PayerCareSource
    PolicyLoargys (pegzilarginase-nbln) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewMar 17, 2026
    Next Review DateN/A
    Key ActionSubmit medical prior authorization with documentation of qualifying diagnosis, specialist involvement, baseline plasma arginine of at least 250 μmol/L, and continued dietary protein restriction.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2 yearsMinimum age for initial authorization
    ≥250 μmol/LRequired baseline plasma arginine
    6 monthsInitial authorization duration
    12 monthsAdditional reauthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <200 μmol/LReauthorization plasma arginine goal

    Coverage Criteria

    Initial Therapy

    Covered for initial authorization when ALL of the following are met.

    Initial authorization

    • Diagnosis confirmation

      • Qualifying diagnostic evidence

        • Genetic test results show biallelic pathogenic variants in ARG1.
        • Enzyme assay results show reduced red blood cell arginase activity.<1% of normal

    Continuation Therapy

    Covered for reauthorization when the following requirement is met.

    Continuation therapy: Chart notes show a clinically significant reduction of plasma arginine levels from baseline.Goal <200 μmol/L; normal range 40 to 115 μmol/L

    If the requirement is met, approval is extended for an additional 12 months.

    Conditions or indications not listed in this document are excluded from medical necessity consideration under this policy and should be referred to the Off-Label policy.

    Loargys (pegzilarginase-nbln) is not medically necessary for the treatment of conditions or indications that are not listed in this policy.

    Dosing and Laboratory Parameters

    Baseline plasma arginine
    Required baselinePlasma arginine concentration must be ≥250 μmol/L.
    Dietary conditionThe threshold applies despite adherent dietary protein restriction.
    DocumentationChart notes must document the baseline plasma arginine concentration.
    Starting dose
    Starting dose0.1 mg/kg.
    RouteIntravenous infusion.
    FrequencyOnce weekly.

    Authorization and Documentation Requirements

    Prior Authorization

    Medical Prior Authorization Required

    Medical prior authorization is required for Loargys (pegzilarginase-nbln). Initial authorization is available only when the member meets all policy criteria, including the age, specialist involvement, confirmed ARG1 deficiency, baseline plasma arginine, and dietary protein-restriction requirements.

    • Member is at least 2 years of age.
    • Prescribed by or in consultation with a metabolic specialist, geneticist, or neurologist.
    • ARG1-D is confirmed by biallelic pathogenic ARG1 variants or reduced RBC arginase activity (<1% of normal).
    • Baseline plasma arginine is ≥250 μmol/L despite adherent dietary protein restriction.
    • Treatment continues in conjunction with dietary protein restriction.
    • If all initial requirements are met, authorization is approved for 6 months.
    • Starting dose: 0.1 mg/kg by intravenous infusion once weekly; maximum dose: 0.2 mg/kg once weekly. Titrate and maintain according to plasma arginine level and prescribing information; subcutaneous dosing may begin after 8 weeks.

    Condition Overview

    Arginase 1 deficiency (ARG1-D) is a rare inherited urea cycle disorder caused by deficient ARG1 enzyme activity. This disrupts urea-cycle metabolism, resulting in elevated plasma arginine and neurologic manifestations such as lower-limb spasticity.

    Key Definitions

    Arginase 1 deficiency (ARG1-D)
    DisorderA rare inherited urea cycle disorder.
    CauseARG1 gene mutations or markedly reduced arginase enzyme activity.
    Biochemical consequenceElevated plasma arginine.
    Urea cycle disorder
    PathwayThe urea cycle is the metabolic pathway that clears nitrogen waste from the body as urea.
    Disorder definitionUrea cycle disorders are rare inherited deficiencies in one of the enzymes involved in the urea cycle.
    Consequence

    Initial Authorization

    Initial Authorization

    Initial authorization requires ALL of the following clinical, diagnostic, specialist, laboratory, and dietary criteria.

    Initial Loargys therapy

    • Diagnosis confirmation

      • Qualifying diagnostic evidence

        • Genetic test results show biallelic pathogenic variants in ARG1.
        • Enzyme assay results show reduced red blood cell arginase activity.<1% of normal

    Reauthorization

    Reauthorization

    Reauthorization is available when the following requirement is met.

    Reauthorization: Chart notes must show a clinically significant reduction of plasma arginine levels from baseline.Goal plasma arginine <200 μmol/L; normal range 40 to 115 μmol/L

    Approval is for an additional 12 months when the requirement is met.

    Loargys Dose Limits

    Loargys
    Starting dose0.1 mg/kg by intravenous infusion once weekly.
    Maximum dose0.2 mg/kg once weekly.
    Titration and maintenanceTitrate and maintain according to plasma arginine level and prescribing information.
    Administration changeMay switch to subcutaneous dosing after 8 weeks.

    Administration Setting

    Billing Rule

    Administer initial dosing by weekly IV infusion

    Administer the initial dose by intravenous infusion once weekly in the office. The medication may switch to subcutaneous dosing after 8 weeks.

    • Starting dose: 0.1 mg/kg by intravenous infusion once weekly.
    • Maximum dose: 0.2 mg/kg once weekly.
    • Titrate and maintain according to plasma arginine level and prescribing information.
    Policy Summary
    PayerCareSource
    PolicyLoargys (pegzilarginase-nbln) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewMar 17, 2026
    Next Review DateN/A
    Key ActionSubmit medical prior authorization with documentation of qualifying diagnosis, specialist involvement, baseline plasma arginine of at least 250 μmol/L, and continued dietary protein restriction.
    SourceLink
    On This Page
    Coverage CriteriaDosing and Laboratory ParametersAuthorization and Documentation RequirementsCondition OverviewKey DefinitionsInitial AuthorizationReauthorizationLoargys Dose LimitsAdministration Setting
    Maximum dose
    Maximum dose0.2 mg/kg.
    FrequencyOnce weekly.
    Dose ceilingThe maximum permitted Loargys dose is 0.2 mg/kg once weekly.
    Normal plasma arginine range
    Normal range40 to 115 μmol/L.
    Lower limit40 μmol/L.
    Upper limit115 μmol/L.
    Reauthorization plasma arginine goal
    Reauthorization goalPlasma arginine must be below 200 μmol/L.
    Required evidenceChart notes must show a clinically significant reduction from baseline.
    Reference rangeThe normal plasma arginine range is 40 to 115 μmol/L.
    Documentation Required

    Initial Authorization Documentation

    For initial authorization, providers must submit chart notes and clinical documentation supporting the diagnosis and treatment criteria. Documentation must establish the member’s baseline plasma arginine and confirm ARG1-D through qualifying genetic or enzyme testing.

    • Chart notes documenting baseline plasma arginine (pArg) concentration of ≥250 μmol/L despite adherent dietary protein restriction.
    • Genetic test results showing biallelic pathogenic variants in ARG1, or enzyme assay results showing reduced RBC arginase activity (<1% of normal).
    • Documentation that the prescription is from or in consultation with a metabolic specialist, geneticist, or neurologist.
    • Documentation that Loargys will be used with continued dietary protein restriction.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, chart notes must demonstrate a clinically significant reduction in plasma arginine from the member’s baseline. When all reauthorization requirements are met, coverage is approved for an additional 12 months.

    • Normal plasma arginine range: 40–115 μmol/L.
    • Treatment goal: plasma arginine <200 μmol/L.
    Denial Risk

    Authorization or Reauthorization Criteria Must Be Met

    Failure to meet any applicable authorization or reauthorization criterion creates a denial risk. Initial authorization will not be approved unless every listed initial requirement is documented; reauthorization will not be approved unless chart notes show a clinically significant reduction in plasma arginine from baseline.

    • Missing or inadequate age, specialist-prescriber, ARG1-D confirmation, baseline pArg, or dietary protein-restriction documentation may result in non-approval.
    • Failure to demonstrate the required clinically significant plasma arginine reduction may result in non-approval of reauthorization.
    Denial Risk

    Unlisted Indications

    Loargys is not medically necessary under this policy for conditions or indications not listed in the document. For any other indication, refer to the Off-Label policy.

    • Unlisted indications are not covered as medically necessary under this policy.
    • Direct requests for other indications to the Off-Label policy.
    Enzyme deficiency makes ureagenesis defective and causes ammonia to accumulate.